Spyre CFO sells shares, exercises stock options

Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows executed a planned option exercise and share sale on Common Stock.

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows executed a planned option exercise and share sale on Common Stock. On May 1, 2026, he sold 12,500 shares of Common Stock in an open-market transaction at $71.37 per share, pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

The same day, he exercised stock options to acquire 12,500 shares of Common Stock at an exercise price of $14.50 per share. Following these transactions, he directly holds 97,994 shares of Common Stock, which include 67,476 restricted stock units scheduled to vest in two equal installments on September 1, 2026 and September 1, 2027, subject to continued employment. He also retains stock options representing a right to purchase 404,857 shares of Common Stock, vesting over several years.

Insider Trade Summary 10b5-1

Exercise and Sale: 12,500 shares ($711K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Burrows Scott L

Role Chief Financial Officer

Sold 12,500 shs ($892K)

Approx. gross sale proceeds $892K

Approx. exercise cost $181K

Approx. pre-tax spread $711K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	12,500	$0.00	$0.00
Exercise	Common Stock	12,500	$14.50	$181K
Sale	Common Stock	12,500	$71.37	$892K

Holdings After Transaction: Stock Option (Right to Buy) — 382,357 contracts (Direct); Common Stock — 97,994 shares (Direct)

Footnotes (3)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
2. F2. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.
3. F3. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Key Figures

Shares sold: 12,500 shares Sale price: $71.37 per share Options exercised: 12,500 shares +5 more

8 metrics

Shares sold 12,500 shares Common Stock sold on May 1, 2026

Sale price $71.37 per share Open-market sale of Common Stock

Options exercised 12,500 shares Stock options exercised into Common Stock on May 1, 2026

Option exercise price $14.50 per share Strike price for exercised stock options

Common shares held 110,494 shares Direct Common Stock holdings after transactions

RSUs included 67,476 RSUs Restricted stock units included in Common Stock holdings

Option grant size 404,857 shares Shares underlying stock option grant

10b5-1 plan adoption date November 10, 2025 Date trading plan for sale was adopted

Key Terms

Rule 10b5-1 trading plan, restricted stock units ("RSUs"), reverse stock split, Stock Option (Right to Buy)

4 terms

Rule 10b5-1 trading plan financial

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units ("RSUs") financial

"Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

reverse stock split financial

"shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023)"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with an expiration date of September 1, 2033"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Spyre Therapeutics (SYRE) report for its CFO?

Spyre Therapeutics CFO Scott L. Burrows sold 12,500 Common Stock shares at $71.37 and exercised options for 12,500 shares at $14.50 on May 1, 2026, as disclosed in the Form 4 filing.

Was the Spyre Therapeutics (SYRE) CFO’s share sale pre-planned?

Yes. The 12,500-share open-market sale on May 1, 2026 was executed under a Rule 10b5-1 trading plan adopted on November 10, 2025, indicating the transaction was scheduled in advance rather than timed opportunistically.

How many Spyre Therapeutics (SYRE) shares does the CFO hold after the transactions?

After the reported transactions, CFO Scott L. Burrows directly holds 110,494 shares of Common Stock. This figure includes 67,476 restricted stock units that convert into shares upon vesting, subject to his continued employment with the company.

What stock options related to Spyre Therapeutics (SYRE) does the CFO retain?

The CFO holds a stock option representing the right to purchase 404,857 shares of Common Stock. One quarter vested on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, contingent on continued employment.

At what prices did the Spyre Therapeutics (SYRE) CFO sell and acquire shares?

On May 1, 2026, the CFO sold 12,500 shares of Common Stock at $71.37 per share and acquired 12,500 shares through an option exercise at an exercise price of $14.50 per share, reflecting a significantly lower strike price.

What are the vesting terms for the Spyre Therapeutics (SYRE) CFO’s RSUs?

The CFO’s 67,476 restricted stock units vest in two equal installments on September 1, 2026 and September 1, 2027. Each RSU converts into one share of Common Stock if he remains employed with Spyre Therapeutics through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 09:35 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burrows Scott L

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		M(1)		12,500	A	$14.5	110,494	D
Common Stock	05/01/2026		S(1)		12,500	D	$71.37	97,994(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.5	05/01/2026		M(1)			12,500	(3)	09/01/2033	Common Stock	12,500	$0	382,357	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

2. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.

3. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)